Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12

Craig-Hallum維持Maravai LifeSciences(MRVI.US)買入評級，下調目標價至12美元

moomoo資訊 · 11/08 10:30 · 評級/大行評級

Craig-Hallum analyst Matt Hewitt maintains $Maravai LifeSciences (MRVI.US)$ with a buy rating, and adjusts the target price from $15 to $12.

According to TipRanks data, the analyst has a success rate of 44.6% and a total average return of -0.5% over the past year.

AnalystRecentRatingAutoNews_79796197611528_20241108_00946829d6ea2a732931ad35d725101cb47f1a27_1731079801099705_mm_en

Furthermore, according to the comprehensive report, the opinions of $Maravai LifeSciences (MRVI.US)$'s main analysts recently are as follows:

Following three consecutive quarters of strong performance in comparison to their forecasts, Maravai Lifesciences experienced a setback due to the challenging biotech spending climate and the irregular ordering patterns from customers that are characteristic of their industry.
Maravai Lifesciences' third-quarter results fell short of expectations, with performance in both segments not meeting projections. The company indicated a decline in research/discovery demand, an absence of sizable drop-in orders, and some delays in GMP program timing extending into 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Craig-Hallum分析師Matt Hewitt維持$Maravai LifeSciences (MRVI.US)$買入評級，並將目標價從15美元下調至12美元。

根據TipRanks數據顯示，該分析師近一年總勝率為44.6%，總平均回報率為-0.5%。

AnalystRecentRatingAutoNews_79796197611528_20241108_00946829d6ea2a732931ad35d725101cb47f1a27_1731079801099705_mm_tc

此外，綜合報道，$Maravai LifeSciences (MRVI.US)$近期主要分析師觀點如下：

在與其預測相比連續三個季度強勁表現之後，maravai lifesciences由於具有行業板塊特徵的挑戰性生物科技支出環境以及客戶不規律的訂購模式而遭遇挫折。
maravai lifesciences第三季度業績不及預期，兩個業務板塊的表現均未達到預期。公司表示研究/發現需求下降，大額訂單缺失，並且一些GMP計劃的計時延長至2025年。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12

Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12

風險及免責聲明

聲明